Get the Stockscreener App
148.43
0.08%
-0.12
After Hours:
147.17
-1.26
-0.85%
Insmed Inc stock is traded at $148.43, with a volume of 1.46M.
It is down -0.08% in the last 24 hours and down -15.65% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$148.55
Open:
$149.49
24h Volume:
1.46M
Relative Volume:
0.50
Market Cap:
$31.66B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-24.01
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
-2.63%
1M Performance:
-15.65%
6M Performance:
+31.48%
1Y Performance:
+85.79%
1-Day Range:
$145.36
$149.83
1-Week Range:
$145.36
$156.52
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
148.43 | 31.68B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 13,396 Shares of Stock - MarketBeat
Profund Advisors LLC Cuts Stock Holdings in Insmed, Inc. $INSM - MarketBeat
ING Groep NV Makes New $53.79 Million Investment in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Fund Update: 43,686 INSMED (INSM) shares added to CIBC Asset Management Inc portfolio - Quiver Quantitative
Essex Investment Management Co. LLC Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Candriam S.C.A. Has $57.26 Million Stock Position in Insmed, Inc. $INSM - MarketBeat
When Will Insmed Incorporated (NASDAQ:INSM) Become Profitable? - Yahoo Finance
Wellington Shields Capital Management LLC Invests $1.22 Million in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Sold by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
Insider Sell: Martina Flammer Sells Shares of Insmed Inc (INSM) - GuruFocus
Valuation Update: Is Insmed Incorporated stock a buy or sell2025 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 - Yahoo Finance
C WorldWide Group Holding A S Sells 75,000 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 640 Shares - MarketBeat
Insider Selling: Insmed (NASDAQ:INSM) COO Sells 791 Shares of Stock - MarketBeat
William Lewis Sells 3,009 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Truist Financial Corp Sells 7,420 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Stock Holdings Lessened by WCM Investment Management LLC - MarketBeat
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
Insmed Presents Data on TPIP Inhalation Drug for PAH - respiratory-therapy.com
MACD Signal: What are the risks of holding Insmed Incorporated2025 Retail Activity & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Principal Financial Group Inc. Has $124.47 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Keybank National Association OH Has $2.41 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Mid-Cap Biopharmas Flex Their Commercial Muscle - Citeline News & Insights
Whale Trades: What are the risks of holding Insmed IncorporatedMarket Movement Recap & Capital Efficiency Focused Strategies - baoquankhu1.vn
Y Intercept Hong Kong Ltd Decreases Position in Insmed, Inc. $INSM - MarketBeat
Rate Cut: Will Insmed Incorporated outperform its industry peers2025 Trading Volume Trends & Low Drawdown Trading Techniques - baoquankhu1.vn
Bank of New York Mellon Corp Trims Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed (INSM) Sees Surge in Bullish Option Activity - GuruFocus
Morgan Stanley Updates Rating for Insmed (INSM), Adjusts Price T - GuruFocus
New York State Common Retirement Fund Buys 18,123 Shares of Insmed, Inc. $INSM - MarketBeat
Federated Hermes Inc. Acquires 219,838 Shares of Insmed, Inc. $INSM - MarketBeat
What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders - Yahoo Finance
Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions - Yahoo Finance
Insmed (NASDAQ:INSM) Coverage Initiated at Barclays - MarketBeat
Definium Therapeutics Appoints Roger Adsett To Board - citybiz
Definium Therapeutics Appoints Roger Adsett to Board of Directors, Effective from January 29, 2025 - marketscreener.com
J. Safra Sarasin Holding AG Invests $1.09 Million in Insmed, Inc. $INSM - MarketBeat
Definium Therapeutics Appoints Roger Adsett to Board of Directors - Business Wire
Pulmonary Arterial Hypertension Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ribomic, Gmax Biopharm, Novartis, Cereno Scientific AB, Insmed - Barchart.com
Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target - marketscreener.com
Barclays Initiates Coverage on Insmed (INSM) with Overweight Rat - GuruFocus
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress - PR Newswire
EFG Asset Management North America Corp. Reduces Stake in Insmed, Inc. $INSM - MarketBeat
Mutual of America Capital Management LLC Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Strs Ohio Grows Stake in Insmed, Inc. $INSM - MarketBeat
Does Insmed Incorporated have strong fundamentalsJuly 2025 News Drivers & AI Based Buy and Sell Signals - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Insmed, Inc. $INSM - MarketBeat
Setup Watch: What is ROIVs book value per shareWall Street Watch & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):